Nintendo: Earnings Show Switch 2 Demand Surging As Margin Recovery Becomes The Next Test
Nintendo’s (OTCPK:NTDOY) Switch 2 launch has shattered records with 10.36 million units sold, driving sales but pressuring margins. My analysis breaks down why upcoming titles like Pokémon Legends Z-A and Metroid Prime 4 could spark the company’s next profit surge.
CD Projekt Vs. Square Enix: One Valued For Diversification And Catalysts, The Other Priced For 2027
Square Enix (OTCMKTS:SQNNY) trades at just 16× EV/EBITDA versus CD Projekt’s (OTCMKTS:OTGLY) 54×, offering stronger value, diversified revenue, and near-term catalysts. My analysis compares both gaming stocks to reveal why Square Enix’s disciplined reinvestment and efficient growth make it the smarter pick heading into 2026.
Capcom Vs. Bandai Namco: Both Buys, But Bandai Namco Wins On Value And Upside
Capcom (OTCMKTS:CCOEY) and Bandai Namco (OTCMKTS:NCBDY) are both Buy-rated Japanese gaming giants—but Bandai Namco wins on value and upside, trading far below peers despite owning Elden Ring and Dragon Ball.
Nintendo: Switch 2 Cycle Sets Up 60%+ Upside
Nintendo (OTCMKTS: NTDOY) and their Switch 2 are off to a record start with 6M units sold in seven weeks. My analysis shows why strong IP, digital sales, and upcoming releases could drive 60%+ investor returns by 2029.
Monster Beverage: Momentum Brewing, But Shares Are Fairly Priced
Monster Beverage (NASDAQ:MNST) had record Q2 sales and strong balance sheet highlight impressive growth momentum—but with shares trading above intrinsic value, the stock looks fairly priced for now.
Niagen Bioscience: A Great Company Suffering From Stock Dilution
Niagen Bioscience (NASDAQ:NAGE) has a debt-free balance sheet and Q2 beat show momentum—but heavy share dilution and a price ~133% above my DCF give the stock a hold rating.